Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Consensus "Buy": Eighteen analysts rate Xenon Pharmaceuticals a consensus "Buy" (15 buy, 2 strong buy, 1 sell) with an average 1‑year target of $73.13 and individual targets as high as $100.
• Heavy insider selling: CEO Ian Mortimer sold 270,000 shares for about $16.29M on March 9 (leaving 6,000 shares), and insiders have sold roughly 296,707 shares (~$17.85M) in the last 90 days, with insiders owning 4.07% of the stock.
• Negative earnings but sizable market cap: Xenon reported a quarterly EPS loss of ($1.31), missing estimates, and analysts forecast -4.83 EPS for the year; the stock has a $5.58B market cap and trades around $57.72 with a 52‑week range of $28.19–$63.95.

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $73.1250.

XENE has been the subject of several recent research reports. Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a report on Tuesday, February 10th. JPMorgan Chase & Co. boosted their price target on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an "overweight" rating in a research report on Friday, January 9th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a research note on Monday, March 9th. Morgan Stanley set a $97.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Wells Fargo & Company lifted their price target on shares of Xenon Pharmaceuticals from $49.00 to $68.00 and gave the stock an "overweight" rating in a report on Tuesday, March 10th.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $57.72 on Wednesday. The company has a market capitalization of $5.58 billion, a P/E ratio of -13.24 and a beta of 0.65. The company's 50-day simple moving average is $54.09 and its two-hundred day simple moving average is $46.40. Xenon Pharmaceuticals has a one year low of $28.19 and a one year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same quarter in the previous year, the firm posted ($0.84) earnings per share. On average, research analysts expect that Xenon Pharmaceuticals will post -4.83 EPS for the current fiscal year.

Insider Activity

In related news, CEO Ian Mortimer sold 270,000 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares of the company's stock, valued at $361,980. This trade represents a 97.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christopher John Kenney sold 2,771 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $166,564.81. Following the sale, the insider directly owned 4,729 shares in the company, valued at $284,260.19. This trade represents a 36.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 296,707 shares of company stock worth $17,845,365 over the last 90 days. 4.07% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals during the fourth quarter worth approximately $33,000. Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 717 shares during the last quarter. Danske Bank A S purchased a new position in Xenon Pharmaceuticals during the third quarter worth about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $43,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at about $39,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.